IRB #

IRB00008906

Title

GO27834: A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of pinatuzumab vedotin (DCDT2980S) in Combination with Rituximab or Polatuzumab Vedotin (DCDS4501A) in Combination with Rituximab and A Non Randomized phase Ib/II Evaluation of Polatuzumab Vedotin in Combination with Obinutuzumab in Patients with Relapsed or Refractory B-cell Cell Non- Hodgkin’s Lymphoma

Principal Investigator

Andy Chen

Study Purpose

The purpose of this study is to find out the effects, good and/or bad, of two experimental drugs (DCDT2980S and DCDS4501A) each in combination with rituximab, have on you and your cancer.

Medical Condition(s)

Non-Hodgkin's Lymphoma

Eligibility Criteria

Age>17years old
History of relapsed or refractory Follicular Lymphoma or Diffuse Large B-Cell Lymphoma
Have measurable lesions by CT scan
Never received a prior allogeneic stem cell transplant
No history of transformed disease to Diffuse Large B-Cell Lymphoma
No history of severe allergic reaction to monoclonal antibody therapy (like rituximab)

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

1 year of treatment; up to 1 additional year of follow-up

Minors Included

No

Contact

Nan Subbiah, Clinical Trial Manager
503 494-4603
subbiahn@ohsu.edu

OR

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

Genentech, Inc

Recruitment End

12/31/2020

Compensation Provided

No


Go Back